The global next generation diabetes therapy and drug delivery market size is expected to reach $12.27 billion by 2026 from $1.86 billion in 2018, registering a CAGR of 46.6% from 2019 to 2026. The report offers in-depth analysis of the drivers & opportunities, key market segments, top investment pockets, industry trends, and competitive landscape.
Increase in prevalence of diabetes worldwide and surge in healthcare expenditure drive the growth of the market. Moreover, growing awareness about the benefits of next-generation diabetes products are expected to increase the demand for next generation diabetes therapy. However, high cost and lack of variety in products hinder the market growth. On the other hand, ongoing R&D to develop low-cost novel products with fewer side effects and untapped potential in emerging economies create new pathways to the market.
Continuous glucose monitoring (CGM) systems segment to remain dominant throughout forecast period
The CGM systems segment contributed more than 90% of the total market revenue in 2017. It is expected to remain dominant throughout the forecast period due to several advantages such as ease of usage and efficient detection of blood glucose levels. On the other hand, the insulin patches segment is expected to register the highest CAGR of 64.1% from 2019 to 2026, owing to advantages such as painless delivery and better control over blood sugar levels. The report also analyzes oral insulin, inhalable insulin, and artificial pancreas.
Adult population segment to maintain dominance through 2026
Adult population (>14 years) segment held the lion's share of the market in 2017. It is expected to maintain its dominance by 2026 due to the large pool of adult patients suffering from diabetes and high rate of FDA approvals of needle-free devices for adults. However, child population (≤14 years) segment would register the highest CAGR of 44.6% from 2019 to 2026, owing to the rise in incidence among child population, rapid development of drug delivery devices for children, and surge in demand for therapeutic devices for children.
Type 2 diabetes segment to be lucrative through 2026
The Type 2 diabetes segment held the major share in 2017, accounting for nearly nine-tenth of the total market revenue. This segment is expected to register the highest CAGR of 41.2% from 2019 to 2026, owing to the presence of large patient population base and availability of a plethora of drug delivery products. The report also analyzes type 1 diabetes indication.
Diagnostics/clinics segment to retain lead throughout forecast period
Diagnostics/clinics segment accounted for nearly half of the total market revenue in 2017 and is expected to remain dominant throughout the forecast period. This is attributed to the increase in preference for buying healthcare products from diagnostic centers and clinics. However, the home healthcare segment would grow at the fastest CAGR of 50.6% from 2019 to 2026, owing to advancement in drug delivery systems such as inhalable and oral insulin, which ensure ease of administration in home care settings. The report also analyzes the ICUs segment.
North America to lead in terms of revenue by 2026
North America contributed 85.1% of the total market revenue in 2017 and is expected to maintain its lead by 2026. This is due to the high awareness among the patient population regarding the benefits of using next generation diabetes products over conventional products. However, Asia-Pacific is expected to register the highest CAGR of 50.7% from 2019 to 2026, owing to the large pool of diabetic patients and increase in healthcare expenditure.
The report analyzes and forecasts the next generation diabetes therapy and drug delivery market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global next generation diabetes therapy and drug delivery market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the next generation diabetes therapy and drug delivery market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of next generation diabetes therapy and drug delivery market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The main objective of this report is to aid the user in understanding the market as a whole, its definitions, segmentation, market potential, influential trends, and the barriers that it is facing. Meticulous research and analysis were an important part of the report preparation. Those reading the report will be able to get a detailed understanding about the market. Industry experts have verified and checked the data and information that have been taken from credible sources like websites, annual reports of companies, journals, and other resources. In order give the facts and data a pictorial form, diagrams, graphs, pie charts, and other representations have been used. That augments the visual appeal of the report and makes understanding it much easier.
Competitive Landscape is the most valuable part of this report
The key players profiled in this report include Abbott Laboratories, Medtronic, Inc., Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Inc., Senseonics Holding, Inc., Medtech, and Johnson & Johnson.
Other players in the value chain include Synertech, Zosano Pharma Corp., Relmada Therapeutics, Inc., Eli Lilly and Company, and Transdermal Specialties Inc.
Key financial developments of a particular company and product & company overview are some of the elements that help in acquiring information about top vendors in the market. This particular section has also included a SWOT analysis of the companies featured in the report. This will help the audience in knowing about opportunities, strengths, threats and weaknesses that are facing by the key vendors in the chemical and material industry across the world. As the competitive landscape is the most valuable part of any report, it consists of all the required information for the detailed study of top players functioning in the industries. It is also an interesting part to find how exactly these key manufacturers implement various strategies to secure the top rank in the industry. Such an in-depth information is useful for the new entrants into the industry as they would be able to learn a bit from these key vendors. Similarly, the information provided in the research report will also be valuable for the renowned key players as well, as they come to know the strategies of their counterparts to sustain in the competitive industry.
By Product Type
Adult Population (>14years)
Child Population (14years)
Type 1 Diabetes
Type 2 Diabetes
By End User
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Europe Medical Foods Market (By Route Of Administration: Oral, Enteral; By Product Type: Pills, Powders, Others; By Application, By Sales Channel) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Europe Mobility Aids Market (By Product: Rollators, Walkers, Wheelchairs, LTC Beds (Home); By Sector: Public, Private; By Distribution Channels: Online, Offline; By Type of Split) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
U.S. Office-based Labs Market (By Modality: Hybrid, Multi-specialty; By Service: Cardiac, Endovascular Intervention; By Specialist) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
U.S. Virtual Care Market (By Application: Family Medicine, Internal Medicine, Cardiology; By Consultation Mode: Video, Audio, Messaging) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Nasal Packing Devices Market (By Product: Injectable, Gel, Sprays, Dressings; By Type: Bioresorbable, Non-absorbable) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...